234 related articles for article (PubMed ID: 36866734)
41. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
42. Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab.
Ikeda M; Ohshima N; Kawashima M; Shiina M; Kitani M; Suzukawa M
Intern Med; 2022 Mar; 61(5):755-759. PubMed ID: 34393172
[TBL] [Abstract][Full Text] [Related]
43. Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps.
Mandl HK; Miller JE; Beswick DM
Otolaryngol Clin North Am; 2024 Apr; 57(2):225-242. PubMed ID: 37684154
[TBL] [Abstract][Full Text] [Related]
44. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis.
Padoan R; Chieco Bianchi F; Marchi MR; Cazzador D; Felicetti M; Emanuelli E; Vianello A; Nicolai P; Doria A; Schiavon F
J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3225-3227.e2. PubMed ID: 32505716
[No Abstract] [Full Text] [Related]
45. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
46. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.
Canzian A; Venhoff N; Urban ML; Sartorelli S; Ruppert AM; Groh M; Girszyn N; Taillé C; Maurier F; Cottin V; de Moreuil C; Germain V; Samson M; Jachiet M; Denis L; Rieu V; Smets P; Pugnet G; Deroux A; Durel CA; Aouba A; Cathébras P; Deligny C; Faguer S; Gil H; Godeau B; Lifermann F; Phin-Huynh S; Ruivard M; Bonniaud P; Puéchal X; Kahn JE; Thiel J; Dagna L; Guillevin L; Vaglio A; Emmi G; Terrier B;
Arthritis Rheumatol; 2021 Mar; 73(3):498-503. PubMed ID: 33001543
[TBL] [Abstract][Full Text] [Related]
47. Targeting eosinophils: severe asthma and beyond.
Caminati M; Menzella F; Guidolin L; Senna G
Drugs Context; 2019; 8():212587. PubMed ID: 31391853
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?
Agarwal A; Spath D; Sherris DA; Kita H; Ponikau JU
Clin Rev Allergy Immunol; 2020 Oct; 59(2):141-149. PubMed ID: 31073812
[TBL] [Abstract][Full Text] [Related]
49. Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report.
Borekci S; Aydin O; Hatemi G; Gemicioglu B
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):134-7. PubMed ID: 25816417
[TBL] [Abstract][Full Text] [Related]
50. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
51. [Eosinophilic granulomatosis with polyangiitis (EGPA) and allergic bronchopulmonary mycosis (ABPM)].
Taniguchi M; Fukutomi Y
Nihon Rinsho; 2016 Oct; 74(10):1721-1728. PubMed ID: 30551287
[TBL] [Abstract][Full Text] [Related]
52. Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence.
Caminati M; Micheletto C; Norelli F; Olivieri B; Ottaviano G; Padoan R; Piacentini G; Schiappoli M; Senna G; Menzella F
Expert Opin Biol Ther; 2024; 24(1-2):15-23. PubMed ID: 38197326
[TBL] [Abstract][Full Text] [Related]
53. Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study.
Can Bostan O; Duran E; Tuncay G; Cihanbeylerden M; Karadag O; Damadoglu E; Karakaya G; Kalyoncu AF
J Asthma; 2023 May; 60(5):931-937. PubMed ID: 35912568
[No Abstract] [Full Text] [Related]
54. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
55. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan.
Lombardi C; Comberiati P; Ridolo E; Cottini M; Yacoub MR; Casagrande S; Riccò M; Bottazzoli M; Berti A
Drugs; 2024 Jun; ():. PubMed ID: 38849701
[TBL] [Abstract][Full Text] [Related]
56. Real-world super-response to biologics in severe asthma: A French monocentric retrospective cohort study.
Valéry S; Habib-Maillard S; Roche N
Respir Med Res; 2023 Nov; 84():101055. PubMed ID: 37897876
[TBL] [Abstract][Full Text] [Related]
57. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
[TBL] [Abstract][Full Text] [Related]
58. Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies.
Navarro-Mendoza EP; Tobón GJ
Curr Rheumatol Rep; 2018 Apr; 20(5):23. PubMed ID: 29611001
[TBL] [Abstract][Full Text] [Related]
59. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
60. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
